Skip to main content
Erschienen in: Rheumatology International 9/2011

01.09.2011 | Original Article

Polymorphisms of tumor necrosis factor-α promoter region for susceptibility to HLA-B27-positive ankylosing spondylitis in Korean population

verfasst von: Won-Tae Chung, Jung-Yoon Choe, Won Cheoul Jang, Su Min Park, Young Chang Ahn, Il Kyu Yoon, Tae-Hwan Kim, Youn-Hyoung Nam, Sung-Hoon Park, Sung-Won Lee, Seong-Kyu Kim

Erschienen in: Rheumatology International | Ausgabe 9/2011

Einloggen, um Zugang zu erhalten

Abstract

This study designed to assess the relationship between tumor necrosis factor (TNF)-α promoter polymorphisms and disease susceptibility to human leukocyte antigen (HLA)-B27-positive ankylosing spondylitis (AS). One hundred and nineteen HLA-B27+ AS patients, 95 HLA-B27+ healthy controls, and 135 random healthy controls were enrolled in this study. Six single nucleotide polymorphisms (SNPs) of the TNF-α promoter at positions –1031T/C, –863C/A, –857C/T, –646G/A, –308G/A, and –238G/A were analyzed. Differences between groups were evaluated using the chi-square test or Fisher’s exact test. Haplotypes from each SNP were constructed, and differences in haplotypic frequencies between groups were evaluated. There were significant differences in the allelic and genotypic frequencies of 1031T/C, –863C/A, and –857C/T TNF-α promoters polymorphisms between HLA-B27+ AS patients and random controls, but not between patients with AS and HLA-B27+ healthy individuals. TNF-α polymorphisms did not influence the extra-spinal clinical features in patients with AS. The haplotypic sequence –1031T/–863C/–857C/–308G increased the risk of susceptibility to AS compared to random controls (P corr < 0.001, OR = 2.756, 95% CI = 1.894–4.010), whereas the sequence –1031C/–863A/–857C/–308G appeared to be associated with decreased susceptibility to AS compared to random controls (P corr = 0.006, OR = 0.396, 95% CI = 0.231–0.679). This study indicates that TNF-α promoter polymorphism between controls and AS patients with HLA-B27+ genetic background is not associated with susceptibility to AS. However, TNF-α polymorphism, irrespective of HLA-B27, increases risk of susceptibility to AS in general population.
Literatur
1.
Zurück zum Zitat Khan MA (2002) Update on spondyloarthropathies. Ann Intern Med 136:896–907PubMed Khan MA (2002) Update on spondyloarthropathies. Ann Intern Med 136:896–907PubMed
2.
Zurück zum Zitat Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A et al (1991) The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 34:1218–1230PubMedCrossRef Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A et al (1991) The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 34:1218–1230PubMedCrossRef
3.
Zurück zum Zitat Brewerton DA, Hart FD, Nicholls A, Caffrey M, James DC, Sturrock RD (1973) Ankylosing spondylitis and HL-A 27. Lancet 1:904–907PubMedCrossRef Brewerton DA, Hart FD, Nicholls A, Caffrey M, James DC, Sturrock RD (1973) Ankylosing spondylitis and HL-A 27. Lancet 1:904–907PubMedCrossRef
4.
Zurück zum Zitat McGarry F, Neilly J, Anderson N, Sturrock R, Field M (2001) A polymorphism within the interleukin 1 receptor antagonist (IL-1Ra) gene is associated with ankylosing spondylitis. Rheumatology (Oxford) 40:1359–1364CrossRef McGarry F, Neilly J, Anderson N, Sturrock R, Field M (2001) A polymorphism within the interleukin 1 receptor antagonist (IL-1Ra) gene is associated with ankylosing spondylitis. Rheumatology (Oxford) 40:1359–1364CrossRef
5.
Zurück zum Zitat Beyeler C, Armstrong M, Bird HA, Idle JR, Daly AK (1996) Relationship between genotype for the cytochrome P450 CYP2D6 and susceptibility to ankylosing spondylitis and rheumatoid arthritis. Ann Rheum Dis 55:66–68PubMedCrossRef Beyeler C, Armstrong M, Bird HA, Idle JR, Daly AK (1996) Relationship between genotype for the cytochrome P450 CYP2D6 and susceptibility to ankylosing spondylitis and rheumatoid arthritis. Ann Rheum Dis 55:66–68PubMedCrossRef
6.
Zurück zum Zitat Crane AM, Bradbury L, van Heel DA, McGovern DP, Brophy S, Rubin L et al (2002) Role of NOD2 variants in spondylarthritis. Arthritis Rheum 46:1629–1633PubMedCrossRef Crane AM, Bradbury L, van Heel DA, McGovern DP, Brophy S, Rubin L et al (2002) Role of NOD2 variants in spondylarthritis. Arthritis Rheum 46:1629–1633PubMedCrossRef
7.
Zurück zum Zitat François RJ, Neure L, Sieper J, Braun J (2006) Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor α in two patients with early disease and transforming growth factor α in three more advanced cases. Ann Rheum Dis 65:713–720PubMedCrossRef François RJ, Neure L, Sieper J, Braun J (2006) Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor α in two patients with early disease and transforming growth factor α in three more advanced cases. Ann Rheum Dis 65:713–720PubMedCrossRef
8.
Zurück zum Zitat Braun J, Deodhar A, Dijkmans B, Geusens P, Sieper J, Williamson P et al (2008) Ankylosing spondylitis study for the evaluation of Recombinant Infliximab Therapy Study Group. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. Arthritis Rheum 59:1270–1278PubMedCrossRef Braun J, Deodhar A, Dijkmans B, Geusens P, Sieper J, Williamson P et al (2008) Ankylosing spondylitis study for the evaluation of Recombinant Infliximab Therapy Study Group. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. Arthritis Rheum 59:1270–1278PubMedCrossRef
9.
Zurück zum Zitat Davis JC Jr, van der Heijde DM, Braun J, Dougados M, Clegg DO, Kivitz AJ et al (2008) Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 67:346–352PubMedCrossRef Davis JC Jr, van der Heijde DM, Braun J, Dougados M, Clegg DO, Kivitz AJ et al (2008) Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 67:346–352PubMedCrossRef
10.
Zurück zum Zitat Rudwaleit M, Siegert S, Yin Z, Erick J, Thiel A, Radbruch A et al (2001) Low T cell production of TNF-α and IFN-γ in ankylosing spondylitis: its relation to HLA-B27 and influence of the –308 TNF polymorphism. Ann Rheum Dis 60:36–42PubMedCrossRef Rudwaleit M, Siegert S, Yin Z, Erick J, Thiel A, Radbruch A et al (2001) Low T cell production of TNF-α and IFN-γ in ankylosing spondylitis: its relation to HLA-B27 and influence of the –308 TNF polymorphism. Ann Rheum Dis 60:36–42PubMedCrossRef
11.
Zurück zum Zitat Wilson AG, de Vries N, Pociot F, di Giovine FS, van der Putte LB, Duff GW (1993) An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med 177:557–560PubMedCrossRef Wilson AG, de Vries N, Pociot F, di Giovine FS, van der Putte LB, Duff GW (1993) An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med 177:557–560PubMedCrossRef
12.
Zurück zum Zitat Lv K, Chen R, Cai Q, Fang M, Sun S (2006) Effects of a single nucleotide polymorphism on the expression of human tumor necrosis factor-alpha. Scand J Immunol 64:164–169PubMedCrossRef Lv K, Chen R, Cai Q, Fang M, Sun S (2006) Effects of a single nucleotide polymorphism on the expression of human tumor necrosis factor-alpha. Scand J Immunol 64:164–169PubMedCrossRef
13.
Zurück zum Zitat Höhler T, Schäper T, Schneider PM, Meyer zum Büschenfelde KH, Märker-Hermann E (1998) Association of different tumor necrosis factor α promoter allele frequencies with ankylosing spondylitis in HLA-B27-positive individuals. Arthritis Rheum 41:1489–1492PubMedCrossRef Höhler T, Schäper T, Schneider PM, Meyer zum Büschenfelde KH, Märker-Hermann E (1998) Association of different tumor necrosis factor α promoter allele frequencies with ankylosing spondylitis in HLA-B27-positive individuals. Arthritis Rheum 41:1489–1492PubMedCrossRef
14.
Zurück zum Zitat McGarry F, Walker R, Sturrock RD, Field M (1999) The –308.1 polymorphism in the promoter region of the tumor necrosis factor gene is associated with ankylosing spondylitis independent of HLA-B27. J Rheumatol 26:1110–1116PubMed McGarry F, Walker R, Sturrock RD, Field M (1999) The –308.1 polymorphism in the promoter region of the tumor necrosis factor gene is associated with ankylosing spondylitis independent of HLA-B27. J Rheumatol 26:1110–1116PubMed
15.
Zurück zum Zitat Kaijzel EL, Brinkman BM, van Krugten MV, Smith L, Huizinga TW, Verjans GM et al (1999) Polymorphism within the tumor necrosis factor-α(TNF-α) promoter region in patients with ankylosing spondylitis. Hum Immunol 60:140–144PubMedCrossRef Kaijzel EL, Brinkman BM, van Krugten MV, Smith L, Huizinga TW, Verjans GM et al (1999) Polymorphism within the tumor necrosis factor-α(TNF-α) promoter region in patients with ankylosing spondylitis. Hum Immunol 60:140–144PubMedCrossRef
16.
Zurück zum Zitat Verjans GM, Brinkmann BMN, van Doornick CEM, Kijlstra A, Verweij CL (1994) Polymorphism of tumor necrosis factor-alpha (TNF-α) at position –308 in relation to ankylosing spondylitis. Clin Exp Immunol 97:45–47PubMedCrossRef Verjans GM, Brinkmann BMN, van Doornick CEM, Kijlstra A, Verweij CL (1994) Polymorphism of tumor necrosis factor-alpha (TNF-α) at position –308 in relation to ankylosing spondylitis. Clin Exp Immunol 97:45–47PubMedCrossRef
17.
Zurück zum Zitat Fraile A, Nieto A, Beraun Y, Vinasco J, Matarán L, Martín J (1998) Tumor necrosis factor gene polymorphisms in ankylosing spondylitis. Tissue Antigens 51:386–1390PubMedCrossRef Fraile A, Nieto A, Beraun Y, Vinasco J, Matarán L, Martín J (1998) Tumor necrosis factor gene polymorphisms in ankylosing spondylitis. Tissue Antigens 51:386–1390PubMedCrossRef
18.
Zurück zum Zitat Shiau MY, Lo MK, Chang CP, Yang TP, Ho KT, Chang YH (2007) Association of tumour necrosis factor α promoter polymorphisms with ankylosing spondylitis in Taiwan. Ann Rheum Dis 66:562–563PubMedCrossRef Shiau MY, Lo MK, Chang CP, Yang TP, Ho KT, Chang YH (2007) Association of tumour necrosis factor α promoter polymorphisms with ankylosing spondylitis in Taiwan. Ann Rheum Dis 66:562–563PubMedCrossRef
19.
Zurück zum Zitat Zhu X, Wang Y, Sun L, Song Y, Sun F, Tang L et al (2007) A novel gene variation of TNFα associated with ankylosing spondylitis: a reconfirmed study. Ann Rheum Dis 66:1419–1422PubMedCrossRef Zhu X, Wang Y, Sun L, Song Y, Sun F, Tang L et al (2007) A novel gene variation of TNFα associated with ankylosing spondylitis: a reconfirmed study. Ann Rheum Dis 66:1419–1422PubMedCrossRef
20.
Zurück zum Zitat van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361–368PubMedCrossRef van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361–368PubMedCrossRef
21.
Zurück zum Zitat Nieto A, Fraile A, Vinasco J, Martín J (1997) HLA-B*27 typing by PCR-restriction fragment length polymorphism. Tissue Antigens 49:283–286PubMedCrossRef Nieto A, Fraile A, Vinasco J, Martín J (1997) HLA-B*27 typing by PCR-restriction fragment length polymorphism. Tissue Antigens 49:283–286PubMedCrossRef
22.
Zurück zum Zitat Chang HK, Jang WC, Park SB, Nam YH, Lee SS, Park YW et al (2007) The novel -G646A polymorphism of the TNF-α promoter is associated with the HLA-B51 allele in Korean patients with Behçet’s disease. Scand J Rheumatol 36:216–221PubMedCrossRef Chang HK, Jang WC, Park SB, Nam YH, Lee SS, Park YW et al (2007) The novel -G646A polymorphism of the TNF-α promoter is associated with the HLA-B51 allele in Korean patients with Behçet’s disease. Scand J Rheumatol 36:216–221PubMedCrossRef
23.
Zurück zum Zitat Jung HY, Park JS, Park YJ, Kim YJ, Kimm K, Koh IS (2004) HapAnalyzer: minimum haplotype analysis system for association studies. Genomics Inform 2:107–109 Jung HY, Park JS, Park YJ, Kim YJ, Kimm K, Koh IS (2004) HapAnalyzer: minimum haplotype analysis system for association studies. Genomics Inform 2:107–109
24.
Zurück zum Zitat El-Shabrawi Y, Wegscheider BJ, Weger M, Renner W, Posch U, Ulrich S, Ardjomand N et al (2006) Polymorphisms within the tumor necrosis factor-alpha promoter region in patients with HLA-B27-associated uveitis: association with susceptibility and clinical manifestations. Ophthalmology 113:695–700PubMedCrossRef El-Shabrawi Y, Wegscheider BJ, Weger M, Renner W, Posch U, Ulrich S, Ardjomand N et al (2006) Polymorphisms within the tumor necrosis factor-alpha promoter region in patients with HLA-B27-associated uveitis: association with susceptibility and clinical manifestations. Ophthalmology 113:695–700PubMedCrossRef
25.
Zurück zum Zitat Kuo NW, Lympany PA, Menezo V, Lagan AL, John S, Yeo TK et al (2005) TNF-857T, a genetic risk marker for acute anterior uveitis. Invest Ophthalmol Vis Sci 46:1565–1571PubMedCrossRef Kuo NW, Lympany PA, Menezo V, Lagan AL, John S, Yeo TK et al (2005) TNF-857T, a genetic risk marker for acute anterior uveitis. Invest Ophthalmol Vis Sci 46:1565–1571PubMedCrossRef
26.
Zurück zum Zitat Spies T, Morton CC, Nedospasov SA, Fiers W, Pious D, Strominger JL (1986) Genes for the tumor necrosis factors α and β are linked to the human major histocompatibility complex. Proc Natl Acad Sci USA 83:8699–8702PubMedCrossRef Spies T, Morton CC, Nedospasov SA, Fiers W, Pious D, Strominger JL (1986) Genes for the tumor necrosis factors α and β are linked to the human major histocompatibility complex. Proc Natl Acad Sci USA 83:8699–8702PubMedCrossRef
28.
Zurück zum Zitat Jacob CO, Fronek Z, Lewis GD, Koo M, Hansen JA, McDevitt HO (1990) Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci USA 87:1233–1237PubMedCrossRef Jacob CO, Fronek Z, Lewis GD, Koo M, Hansen JA, McDevitt HO (1990) Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci USA 87:1233–1237PubMedCrossRef
Metadaten
Titel
Polymorphisms of tumor necrosis factor-α promoter region for susceptibility to HLA-B27-positive ankylosing spondylitis in Korean population
verfasst von
Won-Tae Chung
Jung-Yoon Choe
Won Cheoul Jang
Su Min Park
Young Chang Ahn
Il Kyu Yoon
Tae-Hwan Kim
Youn-Hyoung Nam
Sung-Hoon Park
Sung-Won Lee
Seong-Kyu Kim
Publikationsdatum
01.09.2011
Verlag
Springer-Verlag
Erschienen in
Rheumatology International / Ausgabe 9/2011
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-010-1434-1

Weitere Artikel der Ausgabe 9/2011

Rheumatology International 9/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.